Relay Therapeutics

RLAY

Market cap $1.34B

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.

Chief Corporate Development Officer Peter Rahmer sold more than 40,000 shares of Relay Therapeutics in October. The sale, worth about $300,000, was partially due to company policy regarding vested restricted stock units.

New York City-based Commodore Capital increased its RLAY position by 3,650,000 shares in the third quarter. The transaction value represented 0.7% of Commodore's 13F AUM for the period.

Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Zaki Molvi - Jefferies LLC, Research Division Presentation Zaki Molvi Jefferies LLC, Research Division All right. Good morning, everyone.

Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated  breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company's Board of Directors Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today reported third quarter 2025 financial results and corporate updates.

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November: Guggenheim's 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 11:00-11:25 a.m.

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025.

The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Relay Therapeutics, Inc. (RLAY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.